-
Apr 27, 2024 | 
medrxiv.org | Yoshiya Tanaka |Atsushi Kumanogoh |Tatsuya Atsumi |Tomonori Ishii
COMPETING INTERESTS: YT has received grants from Mitsubishi-Tanabe, Eisai, Chugai, and Taisho; speaker fees and/or honoraria from Eli Lilly, AstraZeneca, Abbvie, Gilead, Chugai, Behringer-Ingelheim, GlaxoSmithKline, Eisai, Taisho, Bristol-Myers Squibb, Pfizer, and Taiho. AK has received grants from Chugai; consulting fees from Eisai; speaker fees and/or honoraria from Asahi Kasei, Astellas, Eisai, GlaxoSmithKline, Chugai, Eli Lilly, Boehringer-Ingelheim, Pfizer, and Bristol-Myers Squibb.
-
Jan 31, 2024 | 
nature.com | Yuki Ishikawa |Nao Tanaka |Mitsuteru Akahoshi |Takashi Matsushita |Akira Oka |Motohisa Yamamoto | +15 more
AbstractHere we report the largest Asian genome-wide association study (GWAS) for systemic sclerosis performed to date, based on data from Japanese subjects and comprising of 1428 cases and 112,599 controls. The lead SNP is in the FCGR/FCRL region, which shows a penetrating association in the Asian population, while a complete linkage disequilibrium SNP, rs10917688, is found in a cis-regulatory element for IRF8.
-
Jan 1, 2024 | 
jrheum.org | Kodai Sakiyama |Michihito Kono |Ai Shimizu |Tatsuya Atsumi
Patients with Sjögren syndrome (SS) have a higher risk of developing malignant lymphoma.1A 68-year-old woman presented with a 2-month history of swollen parotid glands. The patient had psoriatic arthritis and had been treated with secukinumab for 3 months. At presentation, she had bilateral swollen and ulcerated parotid glands (Figure 1A) with sicca symptoms. Laboratory data showed positivity for anti-SSA and anti-SSB antibodies and elevated C-reactive protein (15.2 mg/L).
-
Nov 10, 2023 | 
ard.bmj.com | Roy Fleischmann |Vibeke Strand |Tatsuya Atsumi |Iain B McInnes
AbstractObjectives To investigate the efficacy and safety of otilimab, an antigranulocyte-macrophage colony-stimulating factor antibody, in patients with active rheumatoid arthritis. Methods Two phase 3, double-blind randomised controlled trials including patients with inadequate responses to methotrexate (contRAst 1) or conventional synthetic/biologic disease-modifying antirheumatic drugs (cs/bDMARDs; contRAst 2).
-
Nov 10, 2023 | 
ard.bmj.com | Peter Taylor |Michael E Weinblatt |Iain B McInnes |Tatsuya Atsumi
Anti-GM-CSF otilimab versus sarilumab or placebo in patients with rheumatoid arthritis and inadequate response to targeted therapies: a phase III randomised trial (contRAst 3) Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
-
Oct 5, 2023 | 
acrjournals.onlinelibrary.wiley.com | Tatsuya Atsumi |Sang-Cheol Bae |Hong Gu |Wen-Nan Huang
INTRODUCTION Pulmonary arterial hypertension (PAH) is a rare, progressive, and severe cardiopulmonary disorder (1). In patients with PAH, the small pulmonary arteries are obstructed because of cellular proliferation, fibrosis, and vascular remodeling, leading to premature death from right-sided heart failure (2-4).
-
Sep 12, 2023 | 
ard.bmj.com | Roy Fleischmann |Vibeke Strand |Tatsuya Atsumi |Iain B McInnes
In contRAst 1, otilimab 90 mg resulted in a significantly greater proportion of patients achieving CDAI LDA at week 12 vs placebo, but otilimab 150 mg did not (20.9% (p=0.0188) and 19.8% (p=0.0368) vs 13.9%). In contRAst 2, both doses resulted in a significant difference versus placebo (26.5% and 25.1%, respectively, vs 11.4%, p<0.0001 for both) (figure 2, table 2, online supplemental figure 3).
-
Sep 11, 2023 | 
ard.bmj.com | Peter Taylor |Michael E Weinblatt |Iain B McInnes |Tatsuya Atsumi
Anti-GM-CSF otilimab versus sarilumab or placebo in patients with rheumatoid arthritis and inadequate response to targeted therapies: a phase III randomised trial (contRAst 3) Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
-
Jul 13, 2023 | 
ard.bmj.com | Kuniyuki Aso |Yuichiro Fujieda |Tatsuya Atsumi
http://orcid.org/0000-0001-8601-6377Kuniyuki Aso, http://orcid.org/0000-0003-4705-341XYuichiro Fujieda, Tatsuya Atsumi Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan Correspondence to Dr Yuichiro Fujieda, Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Hokkaido, Japan; edaichi{at}med.hokudai.ac.jp...
-
Jun 4, 2023 | 
pubmed.ncbi.nlm.nih.gov | Hiroshi Nomoto |Tatsuya Atsumi |Hiroshi Iesaka
Skip to main page content Access keysNCBI HomepageMyNCBI HomepageMain ContentMain Navigation Save citation to file Format: Add to My Bibliography Your saved search Name of saved search: Search terms: Frequency: Which day? Which day?
